flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
500 vacancies in the Flemish biotech sector
Over 300 businesses active in the Flemish biotech or life sciences cluster possess 500 open vacancies, in particular for job profiles in production, e.g. (bio)engineers, industrial chemists or ICT experts. In addition, the sector is looking for new staff for research and development. Flanders is among the five most important life sciences clusters in Europe. Here, the cluster provides direct employment to over 20,000 people and indirectly to a further 80,000. That's according to research by flanders.bio and KBC Securities. The figures were made public within the framework of 'knowledge for growth', the annual congress of the biotech and life sciences cluster in Flanders.
Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has completed the preparation of a pre-clinical package for a novel Nanobody® (ALX-1141) in osteoarthritis. As part of the ongoing collaboration between Ablynx and Merck KGaA (Darmstadt, Germany) on this programme, Merck has accepted the pre-clinical package and this has triggered a €15 million milestone payment to Ablynx. Merck is now responsible for further clinical development of the molecule.
Tau prevents synaptic transmission at early stage of neurodegeneration
Tau proteins are involved in more than twenty neurodegenerative diseases, including various forms of dementia. These proteins clump together in patients’ brains to form neuronal tangles: protein aggregation that eventually coincides with the death of brain cells. Prof. Patrik Verstreken’s research team (VIB-KU Leuven) has now discovered how tau disrupts the functioning of nerve cells, even before it starts forming tangles. They immediately suggest a way to intervene in this process.
argenx announces full exercise of underwriters' option to purchase additional ADSs
argenx (Euronext & Nasdaq: ARGX) announced today that the underwriters of its initial public offering in the United States (the "Offering") have exercised their overallotment option to purchase 879,750 additional American Depositary Shares ("ADSs") in full. This option exercise brings the anticipated total gross proceeds from the Offering to approximately $114.7 million from the sale of an aggregate of 6,744,750 ADSs. Each of the ADSs offered represents the right to receive one ordinary share.
Mithra & Gynial sign commercialization agreement for MyringTM in Austria
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced a non-exclusive, 10-year license and supply agreement with Gynial GmbH, for the commercialization of MyringTM, Mithra’s combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA), in Austria. Gynial, an expert in Women’s Health, is the market leader in contraceptives in Austria. Financial details of the agreement were not disclosed.